These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31004299)

  • 1. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
    Bellon JR; Guo H; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Hudis CA; Krop I; Burstein HJ; Winer EP; Tolaney SM
    Breast Cancer Res Treat; 2019 Jul; 176(2):303-310. PubMed ID: 31004299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
    Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy.
    Cao L; Cai G; Xu F; Yang ZZ; Yu XL; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Medicine (Baltimore); 2016 Aug; 95(32):e4230. PubMed ID: 27512838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    Gingras I; Holmes E; De Azambuja E; Nguyen DH; Izquierdo M; Anne Zujewski J; Inbar M; Naume B; Tomasello G; Gralow JR; Wolff AC; Harris L; Gnant M; Moreno-Aspitia A; Piccart MJ; Azim HA
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
    Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
    Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
    Bellon JR; Tayob N; Yang DD; Tralins J; Dang CT; Isakoff SJ; DeMeo M; Burstein HJ; Partridge AH; Winer EP; Krop IE; Tolaney SM
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):117-124. PubMed ID: 34990776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
    Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP
    N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
    Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
    Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
    Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
    Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
    Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
    J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience.
    Diker O; Aktas BY; Ak R; Koylu B; Bas O; Taban H; Guven DC; Olgun P; Kertmen N; Dizdar O; Oksuzoglu B; Aksoy S
    Future Oncol; 2022 Jan; 18(3):323-331. PubMed ID: 34758639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
    Vargas CE; Thorpe CS; Dueck AC; Tenner KS; Davidson NE; Martino S; Pisansky TM; Hwang ES; Halyard MY; Pockaj BA; Perez EA
    Cancer; 2020 Dec; 126(24):5239-5246. PubMed ID: 32931029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.